Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol OTC migraine labeling study shows "superficial" comprehension -- FDA's Lechter.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS LABELING STUDY SHOWS "SUPERFICIAL" UNDERSTANDING of the proposed OTC migraine statements for Excedrin Extra Strength, FDA Division of Drug Marketing, Advertising & Communications Social Science Analyst Karen Lechter, PhD, commented at a July 15 FDA advisory committee meeting. "Potential users who are probable migraine sufferers seem to understand the migraine-specific elements of the label," but that understanding "was at a rather superficial level," Lechter said.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel